Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
X. Badia, L. Lizán, S. Magaz, C. Álvarez Sanz, J. Green & D. Serrano. (2007) Cost-Effectiveness Analysis of Enfuvirtide (ENF) Added to an Optimized Therapy Compared with an Optimized Therapy in Patients with HIV/AIDS. HIV Clinical Trials 8:4, pages 235-245.
Read now
Read now
Articles from other publishers (15)
Pedro Miguel Salcedo Gómez, Masayuki Amano, Sofiya Yashchuk, Akira Mizuno, Debananda Das, Arun K. Ghosh & Hiroaki Mitsuya. (2013)
GRL-04810 and GRL-05010, Difluoride-Containing Nonpeptidic HIV-1 Protease Inhibitors (PIs) That Inhibit the Replication of Multi-PI-Resistant HIV-1
In Vitro
and Possess Favorable Lipophilicity That May Allow Blood-Brain Barrier Penetration
. Antimicrobial Agents and Chemotherapy 57:12, pages 6110-6121.
Crossref
Crossref
Marie-Pierre de Béthune, Vanitha Sekar, Sabrina Spinosa-Guzman, Marc Vanstockem, Sandra De Meyer, Piet Wigerinck & Eric Lefebvre. 2011. Antiviral Drugs. Antiviral Drugs
31
45
.
Erkki Lathouwers, Sandra De Meyer, Inge Dierynck, Tom Van de Casteele, Ludo Lavreys, Marie-Pierre de Béthune & Gaston Picchio. (2011) Virological Characterization of Patients Failing Darunavir/Ritonavir or Lopinavir/Ritonavir Treatment in the Artemis Study: 96-Week Analysis. Antiviral Therapy 16:1, pages 99-108.
Crossref
Crossref
Masaaki Takahashi, Atsushi Hirano, Nami Okubo, Eri Kinoshita, Toshiharu Nomura & Tsuguhiro Kaneda. (2010) Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations. The Journal of Medical Investigation 57:3,4, pages 245-250.
Crossref
Crossref
H. Van Marck, I. Dierynck, G. Kraus, S. Hallenberger, T. Pattery, G. Muyldermans, L. Geeraert, L. Borozdina, R. Bonesteel, C. Aston, E. Shaw, Q. Chen, C. Martinez, V. Koka, J. Lee, E. Chi, M.-P. de Béthune & K. Hertogs. (2009) The Impact of Individual Human Immunodeficiency Virus Type 1 Protease Mutations on Drug Susceptibility Is Highly Influenced by Complex Interactions with the Background Protease Sequence. Journal of Virology 83:18, pages 9512-9520.
Crossref
Crossref
Anton PozniakMilos OpravilGeorge BeattyAndrew HillMarie-Pierre de BéthuneEric Lefebvre. (2008) Effect of Baseline Viral Susceptibility on Response to Darunavir/Ritonavir versus Control Protease Inhibitors in Treatment-Experienced HIV Type 1-Infected Patients: POWER 1 and 2. AIDS Research and Human Retroviruses 24:10, pages 1275-1280.
Crossref
Crossref
Roy T. SteigbigelDavid A. CooperPrincy N. KumarJoseph E. EronMauro SchechterMartin MarkowitzMona R. LoutfyJeffrey L. LennoxJose M. GatellJurgen K. RockstrohChristine KatlamaPatrick YeniAdriano LazzarinBonaventura ClotetJing ZhaoJoshua ChenDesmond M. RyanRand R. RhodesJohn A. KillarLucinda R. GildeKim M. StrohmaierAnne R. MeibohmMichael D. MillerDaria J. HazudaMichael L. NesslyMark J. DiNubileRobin D. IsaacsBach-Yen NguyenHedy Teppler. (2008) Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. New England Journal of Medicine 359:4, pages 339-354.
Crossref
Crossref
L. XuJ. AndersonB. FernsP. CookA. WildfireJ. WorkmanS. GrahamE. Smit. (2008) Genetic Diversity of Integrase (IN) Sequences in Antiretroviral Treatment-Naive and Treatment-Experienced HIV Type 2 Patients. AIDS Research and Human Retroviruses 24:7, pages 1003-1007.
Crossref
Crossref
Christine Katlama. (2008) The POWER and TITAN trials: darunavir/ritonavir in the management of HIV-infected patients. Future HIV Therapy 2:3, pages 229-245.
Crossref
Crossref
Raveendra Dayam, Laith Q. Al-Mawsawi, Zahrah Zawahir, Myriam Witvrouw, Zeger Debyser & Nouri Neamati. (2008) Quinolone 3-Carboxylic Acid Pharmacophore: Design of Second Generation HIV-1 Integrase Inhibitors. Journal of Medicinal Chemistry 51:5, pages 1136-1144.
Crossref
Crossref
Sandra de MeyerTony VangeneugdenBen van BaelenEls de PaepeHerwig van MarckGaston PicchioEric LefebvreMarie-Pierre de Béthune. (2008) Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials. AIDS Research and Human Retroviruses 24:3, pages 379-388.
Crossref
Crossref
Masaaki Takahashi, Mitsuru Konishi, Yuichi Kudaka, Naoya Okumura, Atsushi Hirano, Nami Terahata, Kazuhide Banno & Tsuguhiro Kaneda. (2008) A Conventional LC-MS Method Developed for the Determination of Plasma Raltegravir Concentrations. Biological & Pharmaceutical Bulletin 31:8, pages 1601-1604.
Crossref
Crossref
Dominique J. Pepper, Graeme A. Meintjes, Helen McIlleron & Robert J. Wilkinson. (2007) Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Drug Discovery Today 12:21-22, pages 980-989.
Crossref
Crossref
Nattawat Onlamoon, Nicholas Plagman, Kenneth A Rogers, Ann E. Mayne, Pavel Bostik, Kovit Pattanapanyasat, Aftab A. Ansari & François Villinger. (2007)
Anti-CD3/28 mediated expansion of macaque CD4
+
T cells is polyclonal and provides extended survival after adoptive transfer
. Journal of Medical Primatology 36:4-5, pages 206-218.
Crossref
Crossref
Beatriz Grinsztejn, Bach-Yen Nguyen, Christine Katlama, Jose M Gatell, Adriano Lazzarin, Daniel Vittecoq, Charles J Gonzalez, Joshua Chen, Charlotte M Harvey & Robin D Isaacs. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. The Lancet 369:9569, pages 1261-1269.
Crossref
Crossref